Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. Financial Results: Aurobindo Pharma
(AUROPHARMA)
XNSE:AUROPHARMA, XBOMAUROPHARMA
Aurobindo Pharma Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q2 FY24 Earnings Concall Revenue Growth Revenue grew 25.8% year-on-year to INR7,219 crores, driven by
Aurobindo Pharma Ltd Q1FY24; 10% rise in Profits
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report
Aurobindo Pharma: Driving Growth in the Pharmaceutical Industry
Stock Data: TickerNSE: AUROPHARMAExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+2.46%YTD+54.04%Last 12 Months+26.40% Company Description: Aurobindo, a company based in Hyderabad since 1986, focuses
Alphagraph | Aurobindo Pharma Ltd (NSE: AUROPHARMA): Q4FY23 Results Out; Total Income rises 13% YoY.
Aurobindo Pharma is a leading pharmaceutical company primarily involved in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and
Aurobindo Pharma Limited (AUROPHARMA) Q4 FY23 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE:AUROPHARMA) Q4 FY23 Earnings Concall dated May. 28, 2023. Corporate Participants: Deepti Thakur -- Investor Relations & Corporate Communications
Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY
Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic
Aurobindo Pharma Limited (AUROPHARMA) Q3 FY23 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE:AUROPHARMA) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Deepti Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer Satakarni
Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY
Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since
Aurobindo Pharma Q2FY23; 41% Fall in Profits
Aurobindo Pharma Ltd.‘s revenue in Q2FY23 fell 3% to ₹ 5,739 crores. Consolidated Profit came at ₹ 409 crores showcasing a 41%
Aurobindo Pharma Limited (AUROPHARMA) Q2 FY23 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE: AUROPHARMA) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Deepti Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer
Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/b8g7f6BUs9Y Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: [00:08:34] Prakash Agarwal of Axis Capital asked about
Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet
Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days 4.36% YTD -19.19% Last 12 months -28.17%
Aurobindo Pharma Limited Q1FY23; 32% fall in Profits
Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5
Aurobindo Pharma Q4 FY 2022 Research Tear Sheet
Aurobindo Pharma Limited is an Indian pharmaceutical company. It was established in the year 1986. The founders include Mr. P.V. Ramprasad Reddy,
Aurobindo Pharma Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/ZZNGEHlRimc Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q4 FY22 Earnings Concall Management Update: AUROPHARMA received final approval for 3 ANDAs and
Aurobindo Pharma Ltd (AUROPHARMA) Q4 FY22 Earnings Concall Transcript
Aurobindo Pharma Ltd (NSE: AUROPHARMA) Q4 FY22 Earnings Concall dated May 30, 2022 Corporate Participants: Deepthi Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer
Aurobindo Pharma Q3 FY 2022 Research Tear Sheet
Aurobindo Pharma Limited is an Indian pharmaceutical company. It is based in HITEC City, Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include
Aurobindo Pharma Limited (AUROPHARMA) Q3 FY22 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE :AUROPHARMA) Q3 2022 Earnings Concall Feb. 10, 2022, Corporate Participants: Arvind Bothra -- Investor Relations Department Santhanam Subramanian
Earnings: Aurobindo Pharma results in Q2 2022
Aurobindo Pharma (NSE: AUROPHARMA) reported its second-quarter 2022 earnings results today. The company had a consolidated net profit of ₹696.71 crores with
Aurobindo Pharma Ltd (AUROPHARMA) Q3 FY21 Earnings Concall Transcript
Aurobindo Pharma Ltd (NSE:AUROPHARMA) Q3 FY21 earnings concall dated Feb. 10, 2021. Corporate Participants: Krishna Kiran -- Manager of Investor Relations Santhanam